GS-441524, an RNA‐dependent RNA polymerase (RdRp) inhibitor, is a 1′-CN-substituted
adenine C-nucleoside analog with broad-spectrum antiviral activity. However, the low oral …

Severe acute respiratory disease coronavirus 2 (SARS-CoV-2) is responsible for the
coronavirus disease 2019 (COVID-19) pandemic. Although a primarily respiratory disease …

Molnupiravir, an antiviral medication widely used against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), acts by inducing mutations in the virus genome during …

Background: Whether hospitalized patients benefit from COVID-19 oral antivirals is
uncertain. Objective: To examine the real-world effectiveness of molnupiravir and …

Covid-19: What is the evidence for the antiviral Paxlovid? | The BMJ Skip to main content
Intended for healthcare professionals Access provided by Google Indexer Subscribe My …

Objective To emulate a randomized target trial to estimate the association between the
antiviral drug molnupiravir and hospital admission or death in adults with SARS-CoV-2 …

Molnupiravir, an antiviral medication that has been widely used against SARS-CoV-2, acts
by inducing mutations in the virus genome during replication. Most random mutations are …

Nucleosides have important therapeutic applications that include antiviral activities against
COVID viruses. It is a common strategy to convert one or multiple of the hydroxyl (OH) units …

Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for
patients with the 2019 coronavirus (COVID-19). However, little is known about their …

The COVID-19 Committee of the Lincei Academy has reviewed the scientific evidence
supporting the efficacy and safety of existing and new drugs/biologics for the preventing and …